A Phase I study of TSU-68 in combination with S-1 in patients with advanced hepatocellular carcinoma who are not candidates for conventional therapy

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221925

Enrollment

Registered

2012-09-25

Start date

2012-09-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

investigational material(s) Generic name etc : TSU-68, S-1 INN of investigational material : orantinib, tegafur, gimeracil, oteracil potassium Therapeutic category code : 42- Antineoplastic agents Dos

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Age >=20 - ECOG performance status 0-1 - Patients who did not respond to surgery, RFA, TAE

Exclusion criteria

Exclusion criteria: - Large amount of pleural effusion or ascites - Esophageal varices - Simultaneously active double cancer

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Time to progression, Response rate, Overall survival	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026